← All trials
NCT04827056
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Apr 30, 2023
- First posted
- Apr 1, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 10
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pharmacotherapies for Alcohol and Substance Abuse ConsortiumLead sponsor
- Department of DefenseCollaborator
- Department of Veteran AffairsOverall official - principal investigator
- Department of Veteran AffairsCollaborator
- Yale UniversityCollaborator
- Department of DefenseCollaborator
- RTI InternationalCollaborator
- BioXcel Therapeutics IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.